Cargando…

Massive Bleeding as the First Clinical Manifestation of Metastatic Prostate Cancer due to Disseminated Intravascular Coagulation with Enhanced Fibrinolysis

Disseminated intravascular coagulation (DIC) is the most frequent coagulation disorder associated with metastatic prostate adenocarcinoma. However, DIC with enhanced fibrinolysis as an initial presentation of prostate cancer is extremely rare. The appropriate treatment to control bleeding in these s...

Descripción completa

Detalles Bibliográficos
Autores principales: Palma Anselmo, Mónica, Nobre de Jesus, Gustavo, Lopes, João Madeira, Victorino, Rui M. M., Meneses Santos, João
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075599/
https://www.ncbi.nlm.nih.gov/pubmed/27803823
http://dx.doi.org/10.1155/2016/7217915
_version_ 1782461892933976064
author Palma Anselmo, Mónica
Nobre de Jesus, Gustavo
Lopes, João Madeira
Victorino, Rui M. M.
Meneses Santos, João
author_facet Palma Anselmo, Mónica
Nobre de Jesus, Gustavo
Lopes, João Madeira
Victorino, Rui M. M.
Meneses Santos, João
author_sort Palma Anselmo, Mónica
collection PubMed
description Disseminated intravascular coagulation (DIC) is the most frequent coagulation disorder associated with metastatic prostate adenocarcinoma. However, DIC with enhanced fibrinolysis as an initial presentation of prostate cancer is extremely rare. The appropriate treatment to control bleeding in these situations is challenging, controversial, and based on isolated case reports in the literature. A 66-year-old male presented at the emergency department with acute severe spontaneous ecchymoses localized to the limbs, laterocervical hematoma, and hemothorax. Prostate specific antigen level was 385 μg/L, bone scintigraphy revealed multiple bone metastases, and prostate biopsy confirmed adenocarcinoma (Gleason 9; 4 + 5). Laboratory investigation showed a pattern of enhanced fibrinolysis rather than the more common intravascular coagulation mechanism. Epsilon aminocaproic acid in monotherapy was initiated with a clear and rapid control of bleeding manifestations. This rare case of massive bleeding due to DIC with enhanced fibrinolysis as the first manifestation of prostate cancer suggests that in selected cases where the acute bleeding dyscrasia is clearly associated with a dominant fibrinolysis mechanism it is possible to use an approach of monotherapy with antifibrinolytics.
format Online
Article
Text
id pubmed-5075599
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-50755992016-11-01 Massive Bleeding as the First Clinical Manifestation of Metastatic Prostate Cancer due to Disseminated Intravascular Coagulation with Enhanced Fibrinolysis Palma Anselmo, Mónica Nobre de Jesus, Gustavo Lopes, João Madeira Victorino, Rui M. M. Meneses Santos, João Case Rep Hematol Case Report Disseminated intravascular coagulation (DIC) is the most frequent coagulation disorder associated with metastatic prostate adenocarcinoma. However, DIC with enhanced fibrinolysis as an initial presentation of prostate cancer is extremely rare. The appropriate treatment to control bleeding in these situations is challenging, controversial, and based on isolated case reports in the literature. A 66-year-old male presented at the emergency department with acute severe spontaneous ecchymoses localized to the limbs, laterocervical hematoma, and hemothorax. Prostate specific antigen level was 385 μg/L, bone scintigraphy revealed multiple bone metastases, and prostate biopsy confirmed adenocarcinoma (Gleason 9; 4 + 5). Laboratory investigation showed a pattern of enhanced fibrinolysis rather than the more common intravascular coagulation mechanism. Epsilon aminocaproic acid in monotherapy was initiated with a clear and rapid control of bleeding manifestations. This rare case of massive bleeding due to DIC with enhanced fibrinolysis as the first manifestation of prostate cancer suggests that in selected cases where the acute bleeding dyscrasia is clearly associated with a dominant fibrinolysis mechanism it is possible to use an approach of monotherapy with antifibrinolytics. Hindawi Publishing Corporation 2016 2016-10-10 /pmc/articles/PMC5075599/ /pubmed/27803823 http://dx.doi.org/10.1155/2016/7217915 Text en Copyright © 2016 Mónica Palma Anselmo et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Palma Anselmo, Mónica
Nobre de Jesus, Gustavo
Lopes, João Madeira
Victorino, Rui M. M.
Meneses Santos, João
Massive Bleeding as the First Clinical Manifestation of Metastatic Prostate Cancer due to Disseminated Intravascular Coagulation with Enhanced Fibrinolysis
title Massive Bleeding as the First Clinical Manifestation of Metastatic Prostate Cancer due to Disseminated Intravascular Coagulation with Enhanced Fibrinolysis
title_full Massive Bleeding as the First Clinical Manifestation of Metastatic Prostate Cancer due to Disseminated Intravascular Coagulation with Enhanced Fibrinolysis
title_fullStr Massive Bleeding as the First Clinical Manifestation of Metastatic Prostate Cancer due to Disseminated Intravascular Coagulation with Enhanced Fibrinolysis
title_full_unstemmed Massive Bleeding as the First Clinical Manifestation of Metastatic Prostate Cancer due to Disseminated Intravascular Coagulation with Enhanced Fibrinolysis
title_short Massive Bleeding as the First Clinical Manifestation of Metastatic Prostate Cancer due to Disseminated Intravascular Coagulation with Enhanced Fibrinolysis
title_sort massive bleeding as the first clinical manifestation of metastatic prostate cancer due to disseminated intravascular coagulation with enhanced fibrinolysis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075599/
https://www.ncbi.nlm.nih.gov/pubmed/27803823
http://dx.doi.org/10.1155/2016/7217915
work_keys_str_mv AT palmaanselmomonica massivebleedingasthefirstclinicalmanifestationofmetastaticprostatecancerduetodisseminatedintravascularcoagulationwithenhancedfibrinolysis
AT nobredejesusgustavo massivebleedingasthefirstclinicalmanifestationofmetastaticprostatecancerduetodisseminatedintravascularcoagulationwithenhancedfibrinolysis
AT lopesjoaomadeira massivebleedingasthefirstclinicalmanifestationofmetastaticprostatecancerduetodisseminatedintravascularcoagulationwithenhancedfibrinolysis
AT victorinoruimm massivebleedingasthefirstclinicalmanifestationofmetastaticprostatecancerduetodisseminatedintravascularcoagulationwithenhancedfibrinolysis
AT menesessantosjoao massivebleedingasthefirstclinicalmanifestationofmetastaticprostatecancerduetodisseminatedintravascularcoagulationwithenhancedfibrinolysis